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Abstract
Asthma is a heterogeneous disease of the lower airways including various types of bron-
chial inflammation presenting with different phenotypes and endotypes. Therapeutic 
response of asthmatic phenotypes/endotypes can be predicted by the use of biomarkers 
of inflammation phenotyping, and in recent years, endotyping of asthmatics allows to 
predict who will best respond to anti-inflammatory treatment and optimize quality of 
life of asthmatics by reducing the risk of exacerbations. Based on noninvasive biomarkers 
of inflammations, several of them have been described that are useful in clinical practice. 
Some of the noninvasive biomarkers have a particularly important role in the diagnosis 
and treatment of asthmatics. Monitoring of noninvasive biomarkers, such as fraction of 
exhaled nitric oxide (FENO), cells in sputum, or biomarkers in exhaled breath condensate 
(EBC), two main inflammatory phenotypes have been described: eosinophilic phenotype 
and neutrophilic phenotype. In eosinophilic asthma, as the most prevalent inflammatory 
phenotype, asthmatics have more than 3% eosinophils in the sputum, elevated levels of 
FENO, and elevated leukotriene’s cytokine levels in EBC. The most extensively studied 
biomarkers in asthma are TH2 or more generally T2-related asthmatic endotype. Their 
clinical benefit might be used to phenotype/endotype features of the underlying type of 
inflammation and selection of asthmatics, particularly with severe or difficult-to-treat 
asthma, which most likely will respond to additional biological therapy. In this chapter, 
we summarize the noninvasive biomarkers available for the management of asthmatics.
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1. Introduction
Asthma is a heterogeneous disease which includes a spectrum of different subtypes with 
different inflammation patterns responding differently to different treatments. The most 
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recently updated GINA guidelines address these issues emphasizing the importance of 
standardized diagnosis and appropriate treatment strategies according to asthma pheno-
type and/or endotype [1]. Generally, biomarkers or physiological measures that precisely 
and conclusively define phenotypes and asthma endotypes are missing or are insufficient. 
Several biomarkers have been described in asthma, but most of them including noninva-
sive biomarkers are not commonly available or still need external validation [2]. Many 
of the potential noninvasive biomarkers will be described in this chapter. Normal ranges 
and validation need to be established for most of them, and stability over time must be 
examined in longitudinal studies. The new research is needed about the effects of asthma 
therapy on biomarker measurements, especially for biomarkers which are proposed to 
guide different treatments, like therapy with biologics [3]. Finally, and most importantly, 
the new biomarkers, especially noninvasive, need to be easily sampled and interpreted at 
the point of care in order to provide and improve the diagnosis and treatment of different 
asthma subtypes, especially those which are more severe and therapy resistant. The chal-
lenge is how to identify “high-quality” biomarkers which have high accuracy and robust-
ness that could predict clinical outcomes and therapy response which is of essential in the 
application of the concept of precision medicine.
2. Fraction of exhaled nitric oxide (FENO)
Fraction of exhaled nitric oxide (FENO) (or fractional exhaled NO) is currently the most 
widely used biomarker in the exhaled breath, and it is often increased in asthma, even in 
mild and asymptomatic condition [4]. Fractional exhaled nitric oxide or the modeling of NO 
dynamics of the lung can give more information than a single FENO value. The synthesis 
of NO is mediated by constitutive (endothelial NOS or neuronal NOS) and inducible NO 
synthase (iNOS). Its production is due to oxidation of L-arginine to L-citrulline. iNOS is the 
only isoform correlated with exhaled nitric oxide, and FENO has been considered as a marker 
of eosinophilic inflammation involving small airways [5]. FENO was found to be strongly 
reduced by treatment with inhaled corticosteroids (ICS) [6]. In a general population of asth-
matics, it was found that the FENO threshold that best identified a sputum eosinophil count 
≥3% in patients receiving high dose of ICS was 27 ppb [7]. In a recent paper, it was shown that, 
in severe asthma, FENO, had a lower accuracy than blood eosinophils to identify eosinophilic 
asthma [8], but increased FENO levels have been associated with a good response to ICS [6], 
oral corticosteroids, anti-IgE [9], and anti-IL-4 and anti-IL-13 [10, 11]. FENO is established 
as a marker of inflammation in asthma, but more than 20 years of research have shown that 
it works in certain asthma endotypes (TH2) [12]. Therefore, there is an increasing need for 
useful biomarkers with predictive and prognostic value for the progression of the disease in 
asthmatic patients and their link with clinical treatments.
3. Exhaled breath condensate (EBC)
Exhaled breath condensate (EBC) is the product of cooling and condensation of the exhaled 
aerosol, collected by tidal breathing during 10–30 minutes into a specially designed cooling 
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device [13]. It represents a potentially very useful method for noninvasive diagnosis of asthma 
and other pulmonary diseases. EBC consists of three major components, first being distilled 
water that comes from condensed gas phase of the exhalate. The second component are non-
volatile particles or droplets of different sizes that are aerosolized from the airway lining 
fluid (ALF), and final components are water-soluble volatiles that are exhaled and absorbed 
into the condensing breath [14]. Considering the origin of EBC, a large number of inflamma-
tion, oxidative stress, nitrosative stress biomarkers, or airway acidification indicators such as 
pH, adenosine, ammonia, free radicals, hydrogen peroxide, isoprostanes, leukotrienes, pros-
tanoids, nitrogen oxides, peptides, and cytokines can be detected in EBC and have been stud-
ied last 20 years [15, 16]. These biomarkers can reflect the underlying state of lower airways as 
well as lung inflammation and can be altered in patients with asthma.
The collection procedure and requirements for the EBC collection devices as well as the stor-
age and processing are still not standardized and validated due to many factors that influence 
the final outcome [15]. The final product of the collection is influenced by not only patient 
factors fluid and food intake timing, concurrent medication or drug intake, age, sex, weight, 
height, and disease but also external factors as room temperature, collection temperature, and 
device materials [15]. The volatiles and the nonvolatile particles of the EBC are highly diluted 
so the detection and analytics of the EBC are challenging tasks, furthermore due to the fact 
that there is no generally accepted dilution marker detected yet [16, 17].
4. Exhaled breath temperature (EBT)
Exhaled breath temperature (EBT) is a noninvasive method for detecting and monitoring 
pathological processes based on inflammation in bronchial lumen. According to the fact that 
heat is one of the cardinal signs of inflammation, the measurement of EBT was developed as 
a marker of airway inflammation and therefore used in the study of inflammatory respira-
tory diseases. The use of EBT devices is particularly attractive in patients with asthma who 
largely exhibit significantly higher EBT values compared with healthy subjects; these patients 
are therefore encouraged to use these exhaled thermometers in clinical practice for the main-
tenance of asthma control and in therapeutic management. In the currently available litera-
ture, there are almost 200 articles on the use of EBT in asthma and other respiratory diseases. 
Only few of these studies have assessed EBT measurements, and one recent study provides 
reliable reference values of EBT in healthy subjects. Despite the potential of EBT, it has not 
yet reached the clinical setting, partly because of a lack of standardization and validation of 
the method. However, a recent study deals with these obstacles. There are three groups of 
external temperatures influenced by EBT in different ways [18]. The first group considered 
the cases with external temperature ≤ 23°C In this case, the average EBT was 28.268 ± 2.872°C 
The second group considered cases measured with an external temperature of 23–28°C. In 
this case, EBT was 30.949 ± 2.511°C. The third group showed that if the test is performed with 
an external temperature > 28°C, the EBT was 32.558 ± 1.805°C. Authors did not report any 
influence by other variables, such as weight, height, blood oxygen saturation, lung function, 
area of residence, work, blood pressure, and axillary temperature, on EBT. Their findings are 
consistent with data from other authors [19]. There are several potential advantages of EBT 
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measurements: very easy for patients and requires only a few minutes; it is completely nonin-
vasive and is therefore also suitable for children and patients with severe disease. The device 
is well accepted by patients and ethics committee, it is inexpensive, and it does not affect the 
underlying airway disease [20].
5. Electronic nose (e-Nose)
Exhaled breath contains thousands of volatile organic compounds (VOCs) in gaseous form 
that reflect the metabolic process occurring in the host, which may be used as markers of 
inflammation in the lung or systemically [21]. e-Nose is a portable device, which allows non-
invasive, quick, and real-time pattern analysis of VOC spectra. Current e-Nose devices gener-
ally consist of an array of chemical sensors that specifically identify VOC mixture. Actually, 
e-Nose is a system of artificial sensor with chemical sensors that consists of an array for a 
qualitative and/or quantitative detection and description of VOC profiles or breath prints. 
Due to poor specificity to individual volatiles, chemical sensor arrays are not generally suit-
able for identifying single volatiles in complex mixtures of breath. Combining technologies, 
the high sensitivity of chemical sensor arrays with the high specificity of gas chromatogra-
phy-mass spectrometry (GC-MS), which could mimic the performance of the natural olfac-
tory system in e-Nose, can be used for identifying breath volatiles, as potential new markers 
of inflammations in different asthmatic sub-phenotypes [22, 23]. However, e-Nose technol-
ogy has limitations. The optimal technique for breath collection, sampling, and analysis of 
single-breath volatiles indicating that future methodological studies are required is unknown. 
Miniaturized devices based on nanotechnology with micro- or nano-arrays are seen as a key 
in advancing a new e-Nose device.
Measurement of VOC by e-Nose can discriminate between patients with respiratory disease 
such as asthma and healthy controls. e-Nose breath prints are associated with the level of 
airway inflammation and might be useful in the assessment of asthma severity as well as 
can discriminate patients with fixed asthma from COPD patients with an 88% accuracy [24]. 
Longitudinal monitoring of exhaled metabolites measured by GC-MS and e-Nose can dis-
criminate loss of asthma control [25]. The usefulness of measurement of VOC profiles by 
e-Nose in assessing asthma inflammatory phenotypes still needs to be confirmed.
6. Biomarkers in induced sputum
Induced sputum is a relatively noninvasive mode of airway sampling that provides an oppor-
tunity for analysis of cellular components and infective agents, including bacteria and viruses, 
together with fluid-phase constituents [26]. There are several standardized manuals that are 
available and help to educate health professionals how to perform the technique to the highest 
standard [27]. The application of induced sputum in the assessment of airway pathology has 
grown rapidly, especially after 2002, when European Respiratory Society (ERS) published the 
recommendations for standardization of sputum induction and processing [28, 29]. That is a 
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key component to provide valuable information for clinical decision-making. Sputum is col-
lected after inhalations of hypertonic saline. Although relatively safe, induced sputum requires 
specialized training, equipment, and laboratory processing. Monitoring lung function during 
the induction procedure reduces the risk of excessive bronchoconstriction. Patient’s active 
cooperation is needed for collection, making this technique unsuitable for some patients, espe-
cially for children below the age of 7 years. Induced sputum provides a rich source of soluble 
and cellular biomarkers. The sputum eosinophil percentage is a key biomarker which identi-
fies patients who have eosinophilic and non-eosinophilic asthma phenotypes and correlates 
with severe exacerbations and AHR. Besides eosinophils, other sputum biomarkers are cur-
rently in research. Sputum neutrophils are often related to severe non-eosinophilic asthma 
with fixed airway obstruction. Soluble sputum biomarkers associated with asthma severity are 
IL-4, IL-5, IL-6, IL-12, IL-13, ECP, LT, TNF-α, CSF, TNF-α, and GM-CSF [30]. Biomarkers such 
as IL-8 and neurokinin A correlate with exacerbation, while procollagen synthesis peptides, 
tissue inhibitors of metalloproteinase, or THF-β have been associated with remodeling [31].
The widespread application of induced sputum in asthma proposed several disease phenotypes 
and defined which of these phenotypes respond to the current therapy. In neutrophilic asthma 
phenotype, the level of sputum mRNA expression of Toll-like receptors 2 and 4 as well as CD14 
was high. Thus, this well-tolerated and safe method provides an additional tool to guide the 
clinical management of asthmatic patients [32]. To date induced sputum represents the only non-
invasive measure of airway inflammation that has a clearly proven role in asthma management.
7. Biomarkers in urine of asthmatics
Urine is an easily accessible and noninvasive collectable biofluid containing many informa-
tion about the current metabolic status of the body. Metabolic changes in the body of an asth-
matic patient are reflected in the metabolite concentrations in urine, and the changes during 
asthma exacerbation can also be tracked well by urine metabolite analysis. Asthma, especially 
during exacerbation, causes a high level of oxidative stress due to the pulmonary reaction to 
exacerbation and resulting formation of reactive oxygen compounds that lead to cell damage. 
In children with asthma, the levels of LTE4 are increased in urine and are not altered under 
inhaled corticosteroid (ICS) therapy, but the 5-lipoxygenase inhibitors reduce the urinary 
LTE4 levels. Eosinophil protein X (EPX) is found in the urine of asthma patients, but the levels 
of the EPX fall within 3 months after anti-inflammatory therapy induction [33].
Prostaglandin D2 (PGD2) is released from mast cells, and it causes bronchoconstriction and 
vasodilatation in the airway. PGD2 is metabolized to 9α,11β-PGF2 and excreted in urine. It 
is also increased in patients with asthma, but its production, thus excretion, may be influ-
enced by corticosteroid therapy [33]. Bromotyrosine (BrTyr) is another biomarker that origi-
nates from protein oxidation in eosinophils. Urinary levels of BrTyr are significantly higher in 
patients with asthma and even higher during exacerbation.
It has been suggested in a few studies with a small number of adult patients that during exacer-
bation the levels of threonine, alanine, carnitine, acetyl carnitine, and trimethylamine N-oxide 
Noninvasive Biomarkers of Asthma
http://dx.doi.org/10.5772/intechopen.74486
7
were slightly increased, which can be caused not only by the above-described oxidative stress 
but also by food and drug intake. Some metabolite urine concentrations were lower than usual: 
acetate, citrate, malonate, and others. Alkane and aldehyde levels were found to be increased in 
urine; also, the levels of carnitine and acetyl carnitine, which are essential in the process of fatty 
acid transport into mitochondria, were high in urine of patients with asthma [34]. Other poten-
tial biomarkers such as club cell protein 16 (CC16), as a biomarker of epithelial dysfunction, 
have been studied in urine of patients with asthma. One study in Chinese children showed 
lower levels of CC16 in asthmatic children [35].
8. Noninvasive biomarkers of asthmatic phenotypes
Over the past decade, the most important advance in the field of asthma has been the recogni-
tion of asthma as a syndrome or heterogeneous disease with several clinical presentations or 
phenotypes. Biomarkers help define the specific pathology of different asthma phenotypes 
and identify potential therapeutic targets. However, a number of biomarkers have been iden-
tified that help define asthma phenotypes most likely than reflect responsiveness to specific 
therapies. Noninvasive biomarkers such as FENO or sputum cells usually reflect the main 
inflammatory phenotypes of asthma. Eosinophilic phenotype having more than 3% eosino-
phils in the sputum is likely to reflect ongoing adaptive immunity in response to allergen. 
Several biomarkers of eosinophilic asthma, except the percentage of eosinophil, are easily 
available in clinical practice, such as blood eosinophils, serum-specific IgE, exhaled nitric 
oxide, or serum periostin level. A significant proportion of asthmatic patients, particularly 
those with severe disease, do not have a TH2-enhanced phenotype (TH-2 low) [9, 36]. Patients 
with a non-TH2 phenotype can be further split in two inflammatory phenotypes depending 
on the level of their airway neutrophilic inflammation: paucigranulocytic and neutrophilic 
[37]. Neutrophilic asthma as more than 76% neutrophils in the sputum is thought to reflect 
innate immune system activation in response to pollutants or infectious agents, mixed granu-
locytic asthma when both inflammatory cells are increased, and paucigranulocytic asthma is 
thought to be not inflammatory and characterized by smooth muscle dysfunction. Among 
severe asthmatics, a subgroup characterized by noneosinophilic inflammation was described 
[38]. We currently lack of user-friendly biomarkers of neutrophilic asthma and airway remod-
eling. This absence of biomarkers for these patterns of inflammation has made it difficult to 
recognized subjects who might respond to biologics that target this pathway [38].
9. Noninvasive biomarkers of asthmatic endotypes
Asthma is increasingly recognized as a heterogeneous group of diseases (syndrome) caused by 
multiple inflammatory pathogenic processes or endotypes. Recently, the definition of the term 
“endotype,” describing a specific pathogenic mechanism leading to the clinical presentation 
of asthma. Two major asthmatic endotypes have been recognized: TH2-high, manifested by 
increased eosinophils in the sputum and airways, and TH2-low, with increased neutrophils or a 
paucigranulocytic cells. Using these classifications and specific biomarkers has led to promising 
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new therapeutics, often biologics, especially for TH2-high asthma. Many studies of asthmatic 
endotypes have assessed granulocyte populations in induced sputum. Increased percentage of 
sputum neutrophil usually represents an increase in IL-17-driven neutrophil recruitment or a 
relative reduction in other inflammatory cells such as eosinophils [39]. Thus, neutrophil activa-
tion state rather than number may be a more important indicator of their contribution to asthma 
severity, as an indicator of TH2-low endotype. From the other side, nitric oxide is produced by 
the action of iNOS encoded by the NOS2 gene, and eosinophils are mobilized by chemokines 
such as eotaxin-3 encoded by the CCL26 gene, highly correlated with the TH2 domination. 
Therefore, available noninvasive biomarkers such as sputum cell analysis or FENO can indi-
rectly represent certain type 2-driven inflammation of asthmatic endotype [40]. The TH2-low 
endotype does not have any readily available point-of-care biomarkers, so TH2-low asthma is 
often diagnosed based on a lack of TH2-high biomarkers [41]. The TH2-low endotype charac-
terized greater resistance to steroids and the development of therapies. Advances have been 
made with regard to sputum cytokine analysis and might also help to guide future treatment of 
severe asthma. Several other noninvasive biomarkers have been described in different asthma 
endotypes, but most of them are not commonly available or still need external validation [33].
10. Noninvasive biomarkers and asthma control
Asthma is a heterogeneous inflammatory disorder with several different phenotypes and 
a nonspecific clinical presentation. Even more, the usually used pulmonary function tests 
are insensitive and often normal or do not correspond to the disease evolvement [33]. Given 
the different etiology of asthma subtypes, the therapy is adjusted and needs to be evaluated 
throughout the duration of treatment. For that purpose a number of biomarkers have been 
studied for the last 30 years.
One of the longest in use is the measurement of the fraction of nitric oxide in exhaled breath 
(FENO). Nitric oxide (NO) is generated by three nitric oxide synthase isoenzymes, one of them 
being inducible (NOS2) that produces most of the exhaled NO. In patients with asthma, espe-
cially eosinophilic airway inflammation, the NOS2 overexpression can be reduced by inhaled 
corticosteroid therapy. This effect is used for predicting the efficacy and monitoring of the ICS 
therapy in patients with asthma [33]. However, the FENO measurement results can be influ-
enced by flow rate, nasal contamination, ambient air, age, height, gender, race, spirometry or 
exercise before testing, diet, and smoke exposure [42]. In general, low FENO levels seem to 
be useful in predicting the asthma phenotypes that will respond poorly to ICS treatment [42]. 
When the asthma is responsive to ICS, the FENO levels correspond in a dose-dependent man-
ner with ICS [42]. Nevertheless, the method still needs to be further evaluated in studies with 
standardized protocols.
Exhaled breath has recently been studied in a different setting; namely, after cooling the 
exhaled breath, a condensate (EBC) containing volatile and nonvolatile particles is produced 
and can be analyzed for existence of numerous biomarkers. The acidity of EBC is high in 
asthmatics, but after inducing anti-inflammatory therapy, it rapidly returns to normal val-
ues [33]. The total nitrite/nitrate levels have been found to be increased in pediatric asthma 
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patients compared to healthy controls; still, the results are conflicting regarding the associa-
tion to asthma severity [42]. Levels of H2O2 increase with asthma severity so it plays a role in 
monitoring disease control and response to steroid treatment as the levels correspond with 
inducement of steroid therapy [42]. EBC in patients with asthma contains higher concentra-
tions of 8-isoprostane both in children and in adults, when compared to healthy controls [42]. 
The level of 8-isoprostane is associated with asthma control and severity and, thus, can be 
used as a monitoring tool.
In combination with nitric oxide, interferon-gamma (IFN-γ), and interleukin-4 (IL-4) measure-
ments in EBC, the level of 8-isoprostane can be used as a good marker for assessing asthma 
control [42].
However, there are many indices that the EBC contains biomarkers that could be used as a tool 
to control asthma progression and therapy adjustments; it is still a method primarily used in 
research setting. The metabolomic and proteomic methods are required in order to have EBC 
analysis in clinical use, which subsequently generates low-cost effectiveness of the methods 
at present [43].
Induced sputum is another source of biomarkers that can be used for asthma disease con-
trol. As a method it is safe, noninvasive, and thus usable in pediatrics. It contains cell phase 
(eosinophils and neutrophils) and supernatant with cytokines. Sputum eosinophil count 
is a key marker of asthma severity and responsiveness to steroid therapy. The number of 
eosinophils correlates well with asthma severity and is predictive of asthma exacerbation. 
Elevated levels of eosinophil cationic protein (ECP), IL-4, IL-5, IL-13, TNF-α, IL-6, IL-12, and 
granulocyte macrophage colony stimulator factor have been found in sputum supernatant of 
asthma patients [33]. Several studies have challenged the usage of induced sputum analysis 
for asthma control, but it seems that the results are contradictory so it needs further testing, 
and for the moment, the method has not been proven accurate enough to be used for asthma 
monitoring in childhood asthma [43].
Recently, urine has been studied as one of possible sources of biomarkers for asthma disease 
monitoring. The studies have, so far, found that only leukotriene E4 and bromotyrosine levels 
are high and associated with disease severity, exacerbations, and aspirin intake [33].
11. Noninvasive biomarkers and asthma therapy
The use of biomarkers in asthma is restrictive because knowledge of the asthma phenotypes 
is incomplete. The concept of better endotyping asthma can give precision medicine useful 
data necessary to develop new therapies. Recent trials evaluating biological therapies tar-
geting IgE, IL-5, IL-4/IL-13, and IL-17 have utilized predictive markers to identify patients 
who might benefit from therapy. Multiple biomarkers including sputum eosinophil count, 
blood eosinophil count, FENO, and serum periostin have been used to identify patients 
with a good response to targeted medications (Table 1) [44–47]. Till now, relevant biomark-
ers that can be useful in the management of asthma are mainly related to TH2 response 
Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype10
[45]. These biomarkers are considered more steroid-responsive [38]. The eosinophil counts 
has proven to be useful in the clinical arena in helping to predict short-term response to 
inhaled corticosteroids (ICS) and tailor the dose of ICS in the severe patients [32]. Sputum 
eosinophil percentage acts as a key marker and correlates with severe exacerbations and 
AHR. Also, it can be useful in a panel of biomarkers to select patients who may benefit from 
IL-5 targeted therapies, including reslizumab, mepolizumab, and benralizumab [48]. Blood 
eosinophils as surrogate markers for sputum eosinophilia are associated with relevant out-
comes and are more readily measureable. New evidence supports fraction of exhaled nitric 
oxide (FENO)-based treatment algorithms for cost-effective maintenance of asthma control/
quality of life. Serum and sputum-derived periostin are biomarkers of lung function decline 
and associated with eosinophilic airway inflammation. Biomarker panels may improve pre-
dictive value as shown for the combination of FENO/urinary bromotyrosine in prediction 
Biological sample Exhaled 
air
Sputum Blood Urine
Target Drug FENO eo neu eo IgEa Periostin IL-13 IL-17 DPP-4 LT 4E
T2 biomarkers
Glucocorticoid • •
IgE Omalizumab • • • •
IL-5 Mepolizumab • •
IL-5 Reslizumab • •
IL-5 Benralizumab • •
IL4/IL-13 Dupilumab • • •
IL-13 Lebrikizumab • •
IL-13 Tralokinumab • •
DPA Fevipiprant • •
LT LTA •
Non-T2 biomarkers
Azithromycin • •b •
Clarithromycin •
IL-17 Brodalumab •c
CXCR2 ACD5096 •c
aDetermines eligibility for omalizumab, but the level is not predictive for response
bTrial did not evaluate sputum neutrophil counts
cTrial did not demonstrate clinical improvement
Legend: eo, Eosinophils; neu, neutrophils; IL, interleukin; DPP-4, dipeptidyl peptidase-4; LT 4E, leukotriene 4E; CXCR2, 
CXC chemokine receptor 2 (Adapted according to Medrek et al. [45])
Table 1. Biomarkers predictive of response to different asthma therapies.
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of steroid responsiveness. Novel biological therapies are proven effective in biomarker-
selected populations. Biomarkers including blood eosinophils and FENO are proven to 
have utility for the effective administration of steroidal and novel biological therapies in 
asthma, allowing individualized treatment. According to experience of many investigators, 
the common cause of persistently elevated FENO despite therapy is poor compliance, but 
this marker is not validated [6]. The complexity and heterogeneity of the asthma request 
different approaches of phenotyping patients. Used and clustering omics data will provide 
a better chance of phenotyping asthma based on disease mechanism with composite set 
of markers obtained for each endotype. Probably, new biomarkers will replace currently 
available biomarkers and be more specific for both T2 and non-T2 pathways. According to 
some authors, novel approach is not based on developing new techniques than combining 
known biomarkers to increase their predictive values. Personalized medicine will allow 
more precision therapy and also provide novel targets and new treatment for each defined 
[46]. The future of personalized medicine will depend of availability of accurate and reli-
able predictive biomarkers.
12. Noninvasive biomarkers of childhood asthma
Asthma represents the most common chronic respiratory disease in children. Whereas pre-
school children present with multitrigger and viral wheeze, in school children, asthma 
is usually classified as allergic and non-allergic. For both, the underlying immunologi-
cal mechanisms are not yet quite understood. Treatment is still prescribed unrelated of 
underlying mechanisms, and often asthma control in children has not been achieved. 
Nevertheless, the spectrum of asthma in clinical presentation is broad, and both symptoms 
and lung function may not always reflect the underlying airway inflammation or endotype 
[49]. Therefore, in recent years, following the example of adult asthmatics is trying to dif-
ferentiate specific asthmatic phenotypes as well as endotypes in children. Several studies 
aiming to identify endotypes are underway, and their relevance for clinical monitoring 
and subsequent treatment options is still a subject of discussion [50]. For these reasons, 
the identification of objective biomarkers of childhood asthma phenotype/endotype, which 
may guide diagnosis, management, and treatment of asthmatic children and might have a 
role in the development of personalized approach [51]. That is why the availability of non-
invasive and validated biomarkers to study and monitor disease is of relevance especially 
in childhood asthma [52]. Identification of clinically applicable noninvasive biomarkers 
such as biomarkers in EBC has been of particular interest in personalized diagnosis and 
treatment of asthma in children [53]. The utility of noninvasive biomarkers in routine clini-
cal practice for monitoring inflammation in children with asthma is undefined, apart from 
FENO measurements. Sputum eosinophilia, EBC, and urinary leukotrienes are still not 
applied in routine clinical practice. Despite the development of new biomarkers or new 
immunological molecules, the complex puzzle of childhood asthma is still far from being 
completed (Table 2) [54].
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Biological sample Biomarker Therapy response Diagnostic Prognostic
Exhaled air FENO x x
EBC x x
EBT x
e-Nose x
Sputum eo x x x
neu x
IL-4 x x
IL-5 x
IL-6 x
IL-12 x
IL-13 x
ECP x x
LT x
TNF-α x
CSF x
GM-CSF x
IL-8 x
Neurokinin x
Metalloproteinase x
THF-β x
Procollagen 
synthesis peptides
x
Blood eo x x x
IgE x x
Periostin x x
IL-13 x x
IL-17 x x
DPP-4 x x
Urine LT E4 x x x
EPX x x
11β-PGF2 x x
BrTyr x x
CC16 x
Table 2. Biomarkers in asthma.
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13. Conclusion
Over the past decades, a great emphasis has been put into developing and researching bio-
markers, as well as noninvasive biomarkers in monitoring of inflammation and treatment of 
asthmatics. The three most promising biomarkers in clinical practice currently are analysis 
of cells in induced sputum, FENO, and biomarkers in EBC. In the past years, the progress 
has been made in the discovery, application, and implementation of new, especially non-
invasive biomarkers in asthmatic patients. Although now-available noninvasive biomarkers 
have marked its benefits, their roles are still too limited and nonspecific for identifying at-risk 
patients, recognitions of specific asthma pattern (phenotype or endotype), and selection of 
specific and the most helpful treatment, particularly biologics. In the near future, the role of 
biomarkers in achieving personalized medicine will be critical.
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Abbreviations
ACQ Asthma control questionnaire
AHR Airway hyperreactivity
ALF Airway lining fluid
BrTyr Bromotyrosine
CC16 Club cell protein 16
CXCR2 CXC chemokine receptor 2
DPP-4 Dipeptidyl peptidase-4
EBC Exhaled breath condensate
EBT Exhaled breath temperature
ECP Eosinophil cationic protein
e-Nose Electronic nose
eo Eosinophils
EPX Eosinophil protein X
ERS European Respiratory Society
Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype14
FENO Fraction of exhaled nitric oxide
FEV1 Forced expiratory volume in 1 second
FVC Forced vital capacity
GC-MC Gas chromatography-mass spectrometry
ICS Inhaled corticosteroids
IgE Immunoglobulin E
IL Interleukin
iNOS Inducible nitric oxide synthase
LT 4E Leukotriene 4E
neu Neutrophils
NO Nitric oxide
PGD2 Prostaglandin D2
VOC Volatile organic compound
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